<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092880</url>
  </required_header>
  <id_info>
    <org_study_id>CAIRO7</org_study_id>
    <nct_id>NCT05092880</nct_id>
  </id_info>
  <brief_title>Radioembolization in Elderly/ Fragile Patients With mCRC</brief_title>
  <acronym>CAIRO7</acronym>
  <official_title>Radioembolization in Elderly/Fragile Patients With Unresectable Livermetastases of Colorectal Cancer, CAIRO7 Study of the DCCG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radioembolization (RE) is a minimally invasive treatment with administration of radioactive&#xD;
      microspheres into the hepatic artery via a microcatheter. Since tumors are preferentially&#xD;
      supplied by the hepatic artery, most microspheres get trapped in the tumor. RE has been shown&#xD;
      a feasible and safe procedure for the treatment of unresectable CRC liver metastases. These&#xD;
      data compare favourably with the toxicity data of capecitabine plus bevacizumab, but this&#xD;
      should be validated in a prospective study.&#xD;
&#xD;
      The proposed study investigates the efficacy of RE as an alternative, better tolerated and&#xD;
      more cost-effective treatment option in elderly or frail patients compared to chronic&#xD;
      systemic treatment with comparable progression-free survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale In The Netherlands, ±14.000 people/year are diagnosed with colorectal cancer (CRC),&#xD;
      and 50% of patients already have/will develop distant metastases, most commonly to the liver.&#xD;
      Standard treatment is palliative systemic treatment, which prolongs overall survival (OS). In&#xD;
      only a small subset of patients with liver-only metastases, local treatment (i.e. surgery) of&#xD;
      metastases is possible with curative intent, either initially or after downsizing by&#xD;
      intensive systemic treatment. The average age at CRC diagnosis is 69 yrs, and 30% of CRC&#xD;
      patients are ≥75 yrs. Thus, many patients are too old and/or fragile to allow intensive&#xD;
      systemic regimens or major surgery. In frail/elderly patients the standard treatment is&#xD;
      capecitabine plus an antibody against the vascular endothelial growth factor (VEGF, i.e.&#xD;
      bevacizumab or biosimilar), given until disease progression or unacceptable toxicity,&#xD;
      resulting in a median progression free survival (PFS) of 8.5-9.2 months. Capecitabine-induced&#xD;
      hand-foot syndrome and diarrhoea are the most commonly occurring toxicities. Prolonged&#xD;
      exposure to CTCAE grade 2 toxicity in frail or elderly patients may already significantly&#xD;
      impact quality of life and daily functioning. Therefore, treatments with less toxicity would&#xD;
      be of great value for these patients.&#xD;
&#xD;
      Radioembolization (RE) is a minimally invasive treatment with administration of radioactive&#xD;
      microspheres into the hepatic artery via a microcatheter. Since tumors are preferentially&#xD;
      supplied by the hepatic artery, most microspheres get trapped in the tumor. RE has been shown&#xD;
      a feasible and safe procedure for the treatment of unresectable CRC liver metastases. These&#xD;
      data compare favourably with the toxicity data of capecitabine plus bevacizumab, but this&#xD;
      should be validated in a prospective study.&#xD;
&#xD;
      The proposed study investigates the efficacy of RE as an alternative, better tolerated and&#xD;
      more cost-effective treatment option in elderly or frail patients compared to chronic&#xD;
      systemic treatment with comparable progression-free survival.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      The objective of this randomized phase 2 study is to demonstrate efficacy of a single RE in&#xD;
      terms of PFS in CRC patients with liver-only metastases who are candidates for palliative&#xD;
      systemic treatment with capecitabine plus anti-VEGF antibody (bevacizumab or biosimilar).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To evaluate safety/toxicity.&#xD;
&#xD;
        -  To evaluate cost-effectiveness.&#xD;
&#xD;
        -  To evaluate quality of life (QoL).&#xD;
&#xD;
        -  To evaluate overall survival.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Multi-center, interventional, treatment, randomized phase 2, open label, comparative study.&#xD;
      The study will be conducted within the network of the Dutch Colorectal Cancer Group (DCCG).&#xD;
      Patients will be randomized 1:1 between RE and systemic treatment with capecitabine +&#xD;
      anti-VEGF antibody.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      220 elderly and/or fragile patients with liver-limited, unresectable metastatic colorectal&#xD;
      cancer, previously not systemically treated, who are candidates for systemic treatment with&#xD;
      capecitabine plus an anti-VEGF antibody, will be enrolled in this study. Given the lack of&#xD;
      validated selection criteria for elderly and/or frail this judgement will be left to the&#xD;
      discretion of the local investigator.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Individualized holmium-166 radioembolization (166Ho-RE) will be performed via a catheter&#xD;
      during angiography. Dosimetry-based treatment planning will be individualized using Q-Suite™&#xD;
      software. The comparator, standard systemic treatment, will be given by the local&#xD;
      investigator and will consist of capecitabine orally 1000 mg/m2 bid day 1-14 + anti-VEGF&#xD;
      antibody i.v. 7.5 mg/kg day 1 at 3-weekly cycles, continued until disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      Progression-free survival.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Safety/toxicity.&#xD;
&#xD;
        -  Cost-effectiveness.&#xD;
&#xD;
        -  QoL.&#xD;
&#xD;
        -  Overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2028</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized phase 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event frequency and grade according to CTCAE version 5.0</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC quality of life questionnaire number C30)</measure>
    <time_frame>3.5 years</time_frame>
    <description>For all questionnaires the official manuals will be used to calculate the subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC quality of life questionnaire number CR29)</measure>
    <time_frame>3.5 years</time_frame>
    <description>For all questionnaires the official manuals will be used to calculate the subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Multidimensional Fatigue Inventory: MFI-20)</measure>
    <time_frame>3.5 years</time_frame>
    <description>For all questionnaires the official manuals will be used to calculate the subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness: Medical Consumption Questionnaire (MCQ)</measure>
    <time_frame>4 years</time_frame>
    <description>For all questionnaires the official manuals will be used to calculate the subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness: Productivity Cost Questionnaire (PCQ)</measure>
    <time_frame>4 years</time_frame>
    <description>For all questionnaires the official manuals will be used to calculate the subscales.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Standard of care first-line systemic therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine plus anti-VEGF antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radioembolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radioembolization of liver with holmium-166 microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>radioembolization</intervention_name>
    <description>holmium-166 microspheres</description>
    <arm_group_label>Radioembolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care first-line systemic therapy</intervention_name>
    <description>Capecitabine plus anti-VEGF antibody</description>
    <arm_group_label>Standard of care first-line systemic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have given written informed consent.&#xD;
&#xD;
          2. Female or male patients aged ≥18 years.&#xD;
&#xD;
          3. Metastatic colorectal cancer, with metastases confined to the liver, previously not&#xD;
             systemically treated.&#xD;
&#xD;
          4. Previous local treatment of liver metastases by resection of a maximum of two liver&#xD;
             segments and/or local ablation is allowed.&#xD;
&#xD;
          5. Elderly/frail patients, according to the local investigator not eligible for local&#xD;
             treatments or intensive systemic regimens with combination chemotherapy.&#xD;
&#xD;
          6. ECOG Performance status 0-2 (Table 1).&#xD;
&#xD;
          7. Eligible for systemic treatment with capecitabine + anti-VEGF antibody.&#xD;
&#xD;
          8. Adequate bone marrow (Hb ≥ 6 mmol/L, WBC ≥ 3x109/L, platelets ≥ 100x109/L), liver&#xD;
             (serum bilirubin ≤ 1x upper limit of normal (ULN), ASAT/ALAT ≤ 5x ULN), and renal (GFR&#xD;
             ≥ 40 ml/min) functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous systemic treatment for metastatic disease.&#xD;
&#xD;
          2. Previous adjuvant treatment completed within 6 months prior to randomization.&#xD;
&#xD;
          3. Symptoms of primary tumour, if in situ, that require intervention; prior treatment&#xD;
             with (chemo)radiotherapy and/or resection of primary tumor is allowed.&#xD;
&#xD;
          4. Resection of more than 2 liver segments, 2-stage procedures and/or radiotherapy of&#xD;
             liver metastases.&#xD;
&#xD;
          5. Eligible for more intensive systemic regimens (i.e. doublet or triplet chemotherapy).&#xD;
&#xD;
          6. Eligible for local treatment of liver metastases (e.g. surgical resection, ablation).&#xD;
&#xD;
          7. Presence of extrahepatic metastases; the presence of small (≤ 1 cm) lesions outside&#xD;
             the liver on CT scan that are not clearly suspicious for metastases and/or the&#xD;
             presence of enlarged hilar lymph nodes in the liver up to a maximal diameter of 2 cm&#xD;
             is allowed.&#xD;
&#xD;
          8. Non-correctable INR &gt;2.0.&#xD;
&#xD;
          9. Any serious comorbidity preventing the safe administration of anti-VEGF antibody&#xD;
             treatment. This includes uncontrolled hypertension or treatment with ≥3&#xD;
             antihypertensive drugs, arterial (cerebro)vascular event within the past 12 months,&#xD;
             history of bleeding, history of GI perforation, or presence of fistulae.&#xD;
&#xD;
         10. Pregnancy or breastfeeding.&#xD;
&#xD;
         11. Mental disorders that may compromise patient compliance.&#xD;
&#xD;
         12. Active second malignancy within the previous 5 years, with the exception of adequately&#xD;
             treated basal cell carcinoma of skin and in situ carcinoma of cervix.&#xD;
&#xD;
         13. Body weight over 150 kg (because of maximum table load).&#xD;
&#xD;
         14. Known severe allergy for intravenous contrast fluids.&#xD;
&#xD;
         15. Participation to another investigational study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Marnix Lam</investigator_full_name>
    <investigator_title>Professor of Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

